ArticleBlood cancer journal2025

Comment on: "Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study" by Busque et al.

Ahmet Emre EşkazanPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.